前列腺癌患者血清腺激肽释放酶2检测的临床意义

Detection of Serum Human Kallikrein 2 in Patients with Prostatic Cancer and Its Clinical Significance

[目的]探讨前列腺癌（PCa）患者血清腺激肽释放酶2（human kallikrein 2,hK2）检测的临床意义。[方法]采用酶联免疫吸附试验（ELISA）和放射免疫分析法（RIA）分别检测30例PCa、30例前列腺增生（BPH）患者和30名健康人血清hK2和前列腺特异性抗原（PSA）的水平。并随访12例行根治性前列腺全切术后PCa患者hK2水平。[结果]PCa组hK2水平为78.8±25.2ng/L,明显高于BPH组（25.4±6.28ng/L）和健康组（24.1±4.16ng/L）,差异有统计学意义（P〈0.05）;hK2检测PCa的敏感度、特异性、准确率分别为63.3%,90.0%,76.6%;血清hK2诊断PCa的ROC曲线下面积为0.767（95%CI：0.642-0.891）;12例PCa患者手术前和手术后hK2比较差异有统计学意义（81.5±24.8ng/L vs 38.4±13.5ng/L,P〈0.001）。[结论]血清hk2诊断PCa,可能可以提高其特异性,减少不必要的活检率,有望成为新的PCa检测指标预测高危人群。

[ Purpose ] To investigate the clinical significance of detection of serum human kallikrein 2 （hK2） levels in patients with prostate cancer（PCa）. [Methods ] The levels of hK2 and prostate specific antigen （PSA） in 30 cases with PCa,30 cases with benign prostatichyperplasia （BPH） and 30 healthy person were detected by enzyme-linked immunosorbent assay（ELISA） and radioimmunoassay （RIA）. Twelve eases with PCa after operation were followed up.[ Results] The levels of serum hK2 in PCa group （78.8±25.2ng/L） were significantly higher than that in BPH group （25.4±6.28ng/L） and healthy person（24.1±4.16ng/L）（P〈0.001）,and there were no statistical difference between BPH group and healthy person （P〉0.05）. The sensitivity,specificity and accuracy of hK2 for PCa was 63.3%, 90.0% and 76.6% respectively. The area under ROC curve of hK2 for PCa diagnosis was 0.767（95% CI：0.642-0.891）. There was significant difference between in serum hK2 level of 12 patients before operation and after operation（81.5±24.8ng/L vs 38.4 ± 13.5ng/L, P〈0.001）. [ Conclusions ] Detection of serum hK2 might improve the specificity and reduce unnecessary biopsies in diagnosis of PCa,it may be a new measured marker to predict high-risk population.